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High Prevalence of Peripheral Arterial Disease in Korean Patients 
with Coronary or Cerebrovascular Disease
This prospective study surveyed the prevalence of peripheral arterial disease (PAD) in Korean 
patients with coronary arterial disease (CAD) or cerebrovascular disorder (CVD). From 
March 2010, 576 hospitalized patients in cardiovascular or stroke center were enrolled as 
the study group. Ankle-brachial index (ABI) was measured and the cut-off point for 
diagnosing PAD was  ≤ 0.9 at rest. A total of 424 hospitalized patients in the Department 
of Surgery and aged  ≥ 50 yr was enrolled as the control group. The prevalence of PAD was 
significantly higher in the study group than the control group (7.6% vs 1.7%; P < 0.001). 
To analyze the relationship of other vascular diseases and PAD, the patients were 
regrouped; group A (no CAD or CVD), group B (CAD only), group C (CVD only), and group 
D (CAD and CVD). Compared with group A, those with other vascular diseases (group B, C, 
D) had significantly higher prevalence of PAD, diabetes, dyslipidemia, renal insufficiency 
and claudication. The trend that patients with CAD or CVD are at risk of PAD is observed in 
this cross-sectional study in Koreans. Routine ABI measurement is recommended in these 
high-risk groups for early detection and proper management of PAD.
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ORIGINAL ARTICLE
Cardiovascular Disorders
INTRODUCTION
The risk of peripheral arterial disease (PAD) in patients with cor-
onary artery disease (CAD) or cerebrovascular disorders (CVD) 
is known to be high in Western population (1). The prognosis of 
PAD is worse than that of advanced cancer. However, it is usu-
ally not dealt with much concern (1). Considering patients with 
PAD are at high risk of death from cardiovascular origin, three 
major vascular disorders, including CAD, CVD, and PAD will be 
managed together (2). However, unfortunately, clinical impor-
tance of PAD is usually underestimated, because the majority 
of the patients are neglecting the chronic symptoms of leg isch-
emia (3).
  Ankle-brachial index (ABI) is known to be useful for detect-
ing PAD in both symptomatic and asymptomatic patients (4). 
ABI value of 0.90 or less indicates generally the presence of PAD, 
and lower ABI value is related to higher mortality (5, 6). Many 
reports on the prevalence of PAD in high risk patients have been 
published in Western countries. However, there is few data in 
the prevalence of PAD in Korean population. And also, the prev-
alence of PAD in high risk patients, such as CAD or CVD, is not 
known in Korean population.
  Therefore, we performed this prospective study to survey the 
prevalence of PAD using ankle-brachial index (ABI) in Korean 
patients with CAD or CVD.
MATERIALS AND METHODS
Inclusion and exclusion criteria
Inclusion criteria for the study group were 1) age  ≥ 50 yr old, 
and 2) hospitalized in Seoul National University Hospital with 
the diagnosis of CAD or CVD. Study group included patients 
who were diagnosed as CAD (angina, myocardial infarction) or 
CVD (ischemic stroke, transient ischemic attack) with or with-
out risk factors (diabetes mellitus, hypercholesterolemia, arteri-
al hypertension, smoking, and high body mass index). Patients 
admitted in the Department of Surgery for other diseases dur-
ing the same period and older than 50 yr were enrolled as the Ahn S, et al.  •  High Prevalence of PAD in Patients with CAD or CVD 
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control group.
  Exclusion criteria were previously diagnosed PAD and un-
stable medical or psychological conditions that would compro-
mise the patient’s safety or successful participation in the study. 
Patient who were unwilling to participate in the study or unable 
to provide informed consent were not included. These criteria 
are summarized in Table 1. 
Data Collection
For the study, data on demographics and personal medical his-
tory were obtained by patient interview and electronic medical 
records. Presence of the risk factors for PAD were surveyed, in-
cluding smoking, body mass index (BMI), hypertension, diabe-
tes mellitus (DM), homocysteinemia, renal dysfunction and 
dyslipidemia. Height and weight were measured during the in-
dex admission and BMI was calculated as kg/m
2. Hypertension, 
dyslipidemia, or diabetes were deemed present if diagnosed by 
a physician or controlled with medications. Hypertension was 
defined as a systolic pressure  ≥ 140 mmHg or diastolic blood 
pressure  ≥ 90 mmHg. DM was defined as either taking insulin 
or glucose lowering agents or fasting plasma glucose level  > 140 
mg/dL. Dyslipidemia was defined as total cholesterol level  > 190 
mg/dL, low-density lipoprotein  > 115 mg/dL, high-density lipo-
protein < 40 mg/dL, or triglyceride levels  > 150 mg/dL, and/or 
if patients were taking lipid-lowering drugs, according to the third 
report of the National Cholesterol Education Program (NCEP) (7). 
  For the measurement of ABI, systolic blood pressures in bi-
lateral arms (brachial artery) and ankles (posterior tibial artery 
or dorsalis pedis artery) were measured by trained physician 
assistants using a 10-20 cm sphygmomanometer and a hand-
held Doppler (Hadeco
®, Tokyo, Japan). ABI was calculated by 
dividing the highest ankle systolic pressure by the highest bra-
chial pressure. PAD was defined if ABI was  ≤ 0.9 in either leg. 
Claudication symptom was also noted.
Statistical analysis
The descriptive analysis was expressed with mean ± standard 
deviation of different variables. The odds ratio (OR) and confi-
dence intervals (CI) were calculated. The chi-square test was 
used to perform univariate analysis for categorical variables, 
analysis of variance (ANOVA) and Student t test for continuous 
variables. Fisher exact test was used to compare the overlap in 
vascular diseases affecting different territories between SNUH 
data and TASC II. Logistic regression was used to calculate the 
odds of PAD associated with CAD or CVD, adjusted for differ-
ence in age, diabetes mellitus, and dyslipidemia. All analysis was 
carried out using SPSS V. 17.0 Windows (SPSS Inc., Chicago, IL, 
USA). A P value < 0.05 was considered as statistically significant. 
Ethics statement
The protocol of this study was approved by the Seoul National 
University Hospital (SNUH) Institutional Review Boards (IRB 
No. 1001-002-304), and was performed according to the Decla-
ration of Helsinki. After providing informed consent, one thou-
sand individuals hospitalized in SNUH were enrolled from 
March to August 2010.
RESULTS
Patient demographics and PAD prevalence
A total of 1,000 patients were analyzed, including 576 in the 
study group and 424 in the control group. The patients’ charac-
teristics are shown in Table 2. According to the study design, the 
number of CAD and CVD were significantly higher in the study 
group (P < 0.001, P < 0.001). In the control group, 35 (8.2%) and 
14 (3.3%) patients had histories of CAD and CVD, respectively. 
There were no difference in the smoking history (P = 0.446). The 
prevalence of dyslipidemia was higher in the study group (52.9% 
vs 11.4%, P < 0.001). Interestingly, the study group showed bet-
Table 1. Selection criteria
Inclusion criteria Exclusion criteria
Age  ≥ 50 yr Previously diagnosed PAD
Study Group (n = 576)
   Diagnosed CAD 
      (angina, myocardial infarction, etc.)
   Diagnosed CVD 
      (Transient ischemic attack, stroke, etc.)
Unstable medical or psychological  
   conditions
Control Group (n = 424)
   Hospitalized patients in the Department of  
      Surgery 
Table 2. Demographics and the prevalence of peripheral arterial disease
Parameters
Study group 
(n = 576)
Control group 
(n = 424)
P value
Sex (male) 388 (67.4%) 260 (61.3%) 0.048*
Age (yr) 66.43 ± 8.14 65.23 ± 8.07 0.021*
CAD, No. (%) 483 (83.9%) 35 (8.3%) < 0.001*
CVD, No. (%) 157 (27.3%) 14 (3.3%) < 0.001*
Hypertension, No. (%) 399 (69.3%) 252 (59.4%) 0.001*
Diabetes, No. (%) 202 (35.1%)   90 (21.4%) < 0.001*
Smoking, No. (%) 255 (44.5%) 178 (42.1%) 0.446
Dyslipidemia, No. (%) 304 (52.9%)   42 (11.4%) < 0.001*
FBS (mg/dL) 120.35 ± 44.28 114.33 ± 36.29 0.142
HbA1C (%)   6.63 ± 2.93   6.47 ± 1.37 0.559
Creatinine (mg/dL)    1.21 ± 1.39   0.94 ± 0.26 < 0.001*
Total cholesterol (mg/dL)  148.29 ± 33.14 162.95 ± 42.78 < 0.001*
HDL cholesterol (mg/dL)    42.53 ± 15.62   42.09 ± 12.37 0.778
LDL cholesterol (mg/dL)    86.39 ± 28.87 108.88 ± 61.38 < 0.001*
Triglycerides (mg/dL)  132.71 ± 85.25 134.32 ± 42.41 0.870
Body mass index (kg/m
2)  25.02 ± 3.22  24.03 ± 3.24 < 0.001*
Homocystein (µM/L)  11.61 ± 4.18 11.25 ± 4.31 0.551
Claudication symptom, No. (%) 42 (7.3) 0 (0) < 0.001*
ABI  ≤ 0.9 (%) 44 (7.6)    7 (1.7) < 0.001*
*P < 0.05. CAD, coronary arterial disease; CVD, cerebrovascular disease; FBS, fast-
ing blood sugar; HbA1C, hemoglobin A1C; HDL, high density lipoprotein; LDL, low 
density lipoprotein.Ahn S, et al.  •  High Prevalence of PAD in Patients with CAD or CVD 
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ter lipid profile than the control group (total cholesterol 148.29 
mg/dL vs 162.95 mg/dL, P < 0.001; lower density lipid choles-
terol 86 mg/dL vs 108 mg/dL, P < 0.001). The prevalence of PAD, 
defined by ABI  ≤ 0.9, was significantly higher in the study group 
compared to the control group (7.64% vs 1.65%, P < 0.001). The 
presence of claudication symptoms was significantly higher in 
the study group (7.3% vs 0%, P < 0.001).
Relationship of other vascular diseases and PAD
To analyze the relationship of other vascular diseases and PAD, 
the patients were regrouped; group A (no CAD/no CVD, 38.2%), 
group B (CAD alone, 44.7%), group C (CVD alone, 10%), and 
group D (CAD and CVD, 7.1%). Table 3 shows the baseline char-
acteristics by vascular disease groups. Compared with group A, 
those with major vascular diseases (group B, C, D) had signifi-
cantly higher prevalence of PAD (P < 0.001), diabetes (P < 0.001), 
dyslipidemia (P < 0.001), and claudication symptoms (P < 0.001). 
The mean level of serum creatinine was higher in group D.
  Fig. 1 represents overlaps in vascular diseases affecting dif-
ferent territories. The pattern of overlap was comparable with 
the data from TASC II (Trans-Atlantic Inter-Society Consensus) 
documents on the management of PAD (8, 9). Among the pa-
tients with symptomatic PAD in TASC II, 4.7% had concomitant 
CAD, 1.2% had concomitant CVD and 1.6% had both. And about 
65% of patients with PAD had clinical evidence of other vascu-
lar diseases. In our data, 4.6% had concomitant CAD, 1.3% had 
concomitant CVD and 1.5% had both. And 90% of the patients 
with PAD were associated with CAD or CVD in our survey (P =  
0.462; Fisher exact test).
Comparison of the risk factors for PAD
Results of univariate analysis for all risk factor are shown in       
Table 4. Patients with ABI  ≤ 0.9 were older (69.9 ± 8.7 vs 65.7 ±  
8.05; P < 0.001), had higher prevalence of CAD (72.5% vs 50.7%; 
P = 0.002) and CVD (35.3% vs 16.1%; P < 0.001). Diabetes and 
dyslipidemia were significantly higher in patients with ABI  ≤ 0.9. 
A tendency of higher homocysteine and creatinine level was 
also seen in patients with ABI  ≤ 0.9. By univariate analysis, CAD 
and CVD were associated with an increased prevalence of PAD. 
Especially patients with both CAD and CVD were at highest risk 
Table 3. Relationship of other vascular disease and PAD
Parameters No CAD & CVD (n = 382) CAD alone (n = 447) CVD alone (n = 100) CAD&CVD (n = 71)  P value
Age (yr) 64.7 ± 8.2 66.2 ± 7.8 68.0 ± 8.2 68.0 ± 9.0 < 0.001
Male (%) 62 67 67 63 0.493
Smoker, No. (%) 159 (42) 197 (44) 45 (45) 32 (45) 0.845
Diabetes, No. (%)   82 (22) 150 (34) 33 (33) 27 (38) < 0.001
Hyperte nsion, No. (%) 226 (59) 197 (44) 45 (45) 32 (45) 0.008
Dyslipidemia, No. (%) 26 (8) 249 (56) 34 (36)  37 (52) < 0.001
BMI (kg/m
2) 24.0 ± 3.3 25.1 ± 3.2 24.3 ± 3.1 24.8 ± 3.0 < 0.001
Creatinine (mg/dL)   0.93 ± 0.26   1.16 ± 1.22   1.13 ± 1.18   1.49 ± 2.08 < 0.001
LDL (mg/dL) 105.7 ± 35.1   83.9 ± 38.0 104.3 ± 34.4   87.9 ± 28.0 < 0.001
HbA1c (%)   6.5 ± 1.4   6.5 ± 1.5   6.6 ± 1.1   7.7 ± 7.3 0.008
Homocystein (µM/L) 11.3 ± 4.3 10.9 ± 3.8 11.7 ± 3.9 12.2 ± 5.6 0.625
Claudication, No. (%)   0 (0)    30 (6.7) 4 (4)      8 (11.3) < 0.001
ABI 0.9-1.3, No. (%)     356 (93.2)    411 (91.9) 87 (87)    60 (84.5) 
ABI  ≤ 0.9, No. (%)      5 (1.3)    28 (6.2) 8 (9)      9 (12.7)
ABI  > 1.3, No. (%)    21 (5.5)      8 (1.8) 4 (4)    2 (2.8)
CAD, coronary arterial disease; CVD, cerebrovascular disease; BMI, body mass index; LDL, low density lipoprotein; HbA1C, hemoglobin A1C; LDL, low density lipoprotein; ABI, 
ankle-brachial index; PAD, peripheral artery disease.
TASC II
Fig. 1. Typical overlap in vascular diseases affecting different territories. PAD, periph-
eral artery disease.
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(adjusted odds ratio [OR] 8.076, 95% confidence interval [CI] 
2.309-28.243) (Table 5). 
DISCUSSION
Because atherosclerosis is a systemic disease, major atheroscle-
rotic vascular diseases, including CAD, CVD, and PAD are relat-
ed to each other. PAD represents an independent risk indicator 
of cardiovascular disease and cerebrovascular disease (10). Long-
term prognosis of patients with PAD is significantly worse than 
patients with coronary artery disease (1). Despite its association 
with severe health risks, PAD remains underestimated or even 
neglected by clinicians or general population and routine PAD 
screening is seldom undertaken, especially in Korea (11).     
  To our knowledge, this is the first study ever reported the prev-
alence of PAD in high risk group of Korean patients with CAD 
or CVD. We found a higher prevalence of the unrecognized PAD 
in the study group (patients with CAD or CVD) compared to 
the control group (7.6% vs 1.7%, P < 0.001). The result of this 
study strongly suggests a need for routine screening of PAD in 
the high risk patients in Korea.
  The prevalence of PAD in general population varies depend-
ing on the risk factors, including age, race, and gender. Accord-
ing to a previous study in a rural area in Korea, low ABI (< 0.9) 
was detected in 2.2% of men and 1.8% of women (12). This value 
was lower than that in a Western study showing higher preva-
lence of PAD in African-Americans (7.8%) and Caucasians (4.4%) 
(13). The prevalence of PAD in patients with CAD or CVD will 
also vary from country to country. In TASC II data based on 
REACH survey, 9.5% of patients with CAD alone and 6.7% of 
patients with CVD alone had PAD. Patients with both CAD and 
CVD had PAD in 16% cumulatively (9). In a Slovenian study, a 
total of 42% of patients with CAD and 36% of patients with CVD 
had PAD (14). Although the prevalence of PAD in patients with 
CAD or CVD are higher than that of general population in Korea 
and Western countries, but absolute percentage of PAD seems 
to be low in Korean population. However, we do not have enough 
evidences to conclude that real ethnic difference exists in Korean 
population. Large population-based epidemiologic studies are 
required. 
  The ankle-brachial index (ABI) is considered as a reliable 
method for diagnosing PAD (15). The association of low ABI 
(< 0.90) with risks of all-cause and CAD mortality was well es-
tablished (6). Given the importance of the early detection and 
management of PAD, this diagnostic tool is useful in both symp-
tomatic and asymptomatic patients. Another merit of ABI is that 
it is very easy to measure in the office or bedside and highly re-
producible and reliable (15). Therefore, clinical practitioners 
should be familiar with the ABI measurement and utilize the 
ABI to detect PAD patients early.
  Interestingly, the study group showed better lipid profile than 
the control group. This result might be due to taking medications 
for dyslipidemia. Almost all of the patients (99%) with dyslipid-
emia in the study group were currently receiving lipid-lowering 
therapy.
  This study has some limitations. First, the control group was 
based on hospitalized patients, not in the general population. 
However, the incidence of PAD in the control group in our study 
was comparable with that in population-based researches. Sal-
vatore and colleagues have shown that the overall prevalence of 
undiagnosed PAD in Sicily of Italy was 2.3% (16). We got a simi-
lar result of 1.7% in our control group. The real PAD prevalence 
in Korea should be studied in large population-based epidemi-
ologic studies. Second, our study design is only a cross sectional 
study, not a cohort study. Long-term follow-up cohort studies 
are required to clarify the impacts of PAD on co-existing vascu-
lar disease. Third, diabetes and end stage renal disease are an-
Table 4. Comparison of the presence of cardiovascular risk factors according to the 
ABI values
Parameters ABI  ≤ 0.9 ABI  > 0.9 P value
Number 51 949
Male 35 613 0.557
Age (yr) 69.9 ± 8.7   65.7 ± 8.05 < 0.001
CAD (%) 72.5 50.7 0.002
CVD (%) 35.3 16.1 < 0.001
Hypertension (%) 72.5 64.7 0.252
Diabetes (%) 56.0 27.9 < 0.001
Smoking (%) 54.9 42.9 0.091
Dyslipidemia (%) 52.0 35.8 0.021
FBS (mg/dL) 122.65 ± 49.11 118.93 ± 42.43 0.563
HbA1C (%)   7.04 ± 1.96   6.57 ± 2.73 0.264
Creatinine (mg/dL)   1.60 ± 2.06   1.07 ± 0.99 0.071
Total cholesterol (mg/dL)   161.2 ± 38.11   154.1 ± 38.19 0.201
HDL cholesterol (mg/dL) 38.85 ± 9.76   42.72 ± 15.40 0.090
LDL cholesterol (mg/dL)   95.52 ± 29.57     89.9 ± 37.82 0.315
Triglyceride (mg/dL) 128.72 ± 70.82 133.30 ± 99.16 0.756
Body mass index (kg/m
2) 24.28 ± 3.16 24.61 ± 3.27 0.471
Homocystein (µM/L) 13.39 ± 6.33 11.34 ± 4.03 0.078
Claudication symptoms (%) 60.8 1.2 < 0.001
CAD, coronary arterial disease; CVD, cerebrovascular disease; FBS, fasting blood 
sugar; HbA1C, hemoglobin A1C; HDL, high density lipoprotein; LDL, low density lipo-
protein.
Table 5. Odds ratio for PAD in major vascular diseases 
Vascular 
   diseases
Crude Adjusted* 
OR  
(95% CI)
 P
OR*  
(95% CI)
P
CAD Alone 5.039  
(1.926-13.182)
0.001 4.139  
(1.361-12.585)
0.012
CVD Alone 7.457  
(2.441-22.785)
< 0.001 5.091  
(1.442-17.976)
0.011
CVD and CVD 10.945  
(3.551-33.738)
< 0.001 8.076  
(2.309-28.243)
0.001
Risk of PAD significantly increased with CAD or CVD. *Adjusted for age, diabetes 
mellitus, dyslipidemia. OR, Odds ratio; CI, confidence interval; CAD, coronary arterial 
disease; CVD, cerebrovascular disease; PAD, peripheral artery disease.Ahn S, et al.  •  High Prevalence of PAD in Patients with CAD or CVD 
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other important risk factors for PAD, which were not included 
in this study. That is because the ABI values in these groups of 
patients are not reliable due to the widespread vascular calcifi-
cations, which usually result in higher ABI value due to incom-
pressible arteries. We are now conducting another study in these 
groups using toe-brachial index and aortic calcification index. 
  In conclusion, patients with CAD or CVD have higher risk for 
PAD. ABI should be performed regularly in high-risk patient 
group for early detection and proper management of PAD. 
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